Empirical upfront use of Higher Generation Broad-spectrum Antibiotics: Clinical microbiology correlation-a cross-sectional study
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 777
- 试验地点
- 1
- 主要终点
- To estimate the proportion of patients started on higher generation broad-spectrum antibiotics who have MDR (multidrug-resistant) organisms in index microbiology culture.
研究概览
简要总结
Patients who present to all clinical departments in a tertiary level teaching hospital in South India are considered. Patients who are administered upfront empirical higher generation broad spectrum antibiotics ( vancomycin, linezolid, meropenem, tigecycline, colistin, piperacillin-tazobactam, cefoperazone-sulbactam), who satisy the inclusion criteria are enrolled after taking informed consent.
The data is collected based on a purpose designed proforma. The data collected will be entered into an Excel spreadsheet.
The data collected includes patient demographics, clinical diagnosis, culture and laboratory parameters, and the therapy started
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 99.00 Year(s)（—）
- 性别
- All
入选标准
- •a)Patients above 18 yrs of age b)Patients administered Higher generation broad-spectrum antibiotics empirically c)Culture specimen was taken before starting primary therapy.
排除标准
- •a)Improper documentation of details b)Patients given higher-generation broad-spectrum antibiotics(HGBSA) without index culture specimens taken.
结局指标
主要结局
To estimate the proportion of patients started on higher generation broad-spectrum antibiotics who have MDR (multidrug-resistant) organisms in index microbiology culture.
时间窗: Every 4 weeks
次要结局
- to determine the clinical parameters associated with MDR microbial infections.(1 year)